ESGO-EURACAN-GCIG Uterine sarcoma guidelines

In 2023, the European Society of Gynaecological Oncology (ESGO), the EURACAN, a European Reference Network for all rare adult solid cancers and the Gynecologic Cancer InterGroup (GCIG) have agreed to start a new joint project with the goal of developing guidelines on the complete management of patients with uterine sarcomas, covering low-grade endometrial stromal sarcoma, uterine leiomyosarcoma, high-grade endometrial undifferentiated stromal sarcoma, adenosarcoma of the uterus and other rare types of uterine sarcomas.

An international development group was composed of experts from countries worldwide covering fields of gynaecologic oncology, medical oncology, radiation oncology, radiology, imaging and pathology.

The article was published in October 2024 in the International Journal of Gynaecological Cancer (IJGC).

 

2024 Uterine Sarcomas Guidelines article:

ESGO-EURACAN-GCIG Uterine Sarcomas Guidelines 2024

 

2024 ESGO-EURACAN-GCIG Uterine Sarcomas Guidelines Working Group

The European Society of Gynaecological Oncology (ESGO), the European Reference Networks for Rare Cancers (EURACAN) and the Gynecologic Cancer InterGroup (GCIG) would like to express their sincere gratitude to the international experts panel, who devoted their time and effort to the ESGO-EURACAN-GCIG Guidelines for the management of patients with Uterine Sarcomas.

Name	Country	Institution
Isabelle Ray-Coquard	France	Centre Leon Berard, UNICANCER, Université  Claude  Bernard  Lyon  1,  28, rue  Laennec LYON  France
Paolo Giovanni Casali	Italy	Fondazione IRCCS Istituto Nazionale Tumori Milano, Italy Department of oncology and hemato-oncology, University of Milan, Milan,Italy
Michael Friedlander	Australia	School of Clinical Medicine, UNSW, Sydney, Australia, Department of Medical Oncology, Prince of Wales and Royal Hospital for Women, Randwick, NSW, Australia
Francois Planchamp	France	Institute Bergonié, Lyon, France
Roberta Sanfilippo	Italy	Fondazione IRCCS Istituto Nazionale Tumori Milano
Frederic Amant	Belgium	Department of Oncology, KU Leuven, Leuven, Belgium Department of Gynecology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands
Jean-Yves Blay	France	Centre Leon Berard, UNICANCER, Université  Claude  Bernard  Lyon  1,  28, rue  Laennec LYON  France
Antonio Casado	Spain	Department of medical oncology, University Hospital San Carlos, Madrid (Spain)
Sabrina Croce	France	Biopathology Department, Anticancer Center, Institut Bergonié, Bordeaux, France; INSERM U 1218, Action Unit, Bordeaux, France
Angelo Paolo Dei Tos	Italy	Department of Pathology, Treviso General Hospital Treviso, Padova, Italy Surgical Pathology and Cytopathology Unit, University of Padua School of Medicine, Padua, Italy
Fiona M.Fennessy	United States	Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
Daniela Fischerova	Czech Republic	Gynecologic Oncology Centre, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech R.
Rick Haas	the Netherlands	Department of Radiotherapy, the Netherlands Cancer Institute, Amsterdam the Netherlands Department of Radiotherapy, the Leiden University Medical center, Leiden, the Netherlands
Martee L. Hensley	United States	Department of medicine, gynecologic medical oncology service, Memorial Sloan Kettering Cancer Center, New York, United States Department of medicine, Weill Cornell Medical College, New York, United States
Peter Hohenberger	Germany	Division of Surgical Oncology and Thoracic Surgery, University Medical Center Mannheim, University of Heidelberg, Germany
Sarah Chiang	United States	Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Robin Jones	United Kingdom	Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom
Jae-Weon Kim	Republic of Korea	Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea
Se Ik Kim	Republic of Korea	Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea
Javier Martin-Broto	Spain	Department of medical Oncology, Fundación Jimenez Diaz University Hospital, Madrid, Spain University Hospital General de Villalba, Madrid, Spain Instituto de investigación Sanitaria Fundación Jimenez Diaz, Madrid, Spain
Mehmet Mutlu Meydanli	Turkey	Department of Gynecological Oncology, Medical Point Hospital, Gaziantep, Turkey
Patricia Pautier	France	Institut Gustave-Roussy, Villejuif, Paris, France
Albiruni R Abdul Razak	Canada	Division of medical oncology and hematology, Princess Margaret Cancer Centre, Toronto, Canada Department of medicine, University of Toronto, Toronto, Canada
Jalid Sehouli	Germany	Department of Gynecology with Center of Oncological, Charité/ Universitätsmedizin Berlin, Germany
Winan Van Houdt	the Netherlands	Department of Surgery, the Netherlands Cancer Institute, Amsterdam, the Netherlands
Ignacio Zapardiel	Spain	Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain

 

External Reviewers

102 reviewers - 40 countries

ESGO would also like to thank external reviewers who have taken the time to provide their feedback on the document elaborated in the framework of the ESGO-EURACAN-GCIG Uterine Sarcomas Guidelines project.

2024 Uterine Sarcomas Guidelines - List of external reviewers